NASDAQ:KPTI

Karyopharm Therapeutics Stock Forecast, Price & News

$10.32
-0.23 (-2.18 %)
(As of 06/11/2021 12:00 AM ET)
Add
Compare
Today's Range
$10.16
$10.73
50-Day Range
$8.11
$11.11
52-Week Range
$7.78
$20.99
Volume1.50 million shs
Average Volume1.27 million shs
Market Capitalization$774.93 million
P/E RatioN/A
Dividend YieldN/A
Beta0.28
30 days | 90 days | 365 days | Advanced Chart
Receive KPTI News and Ratings via Email

Sign-up to receive the latest news and ratings for Karyopharm Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Karyopharm Therapeutics logo

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc., a pharmaceutical company, engages in the discovery, development, and commercialization of various drugs directed against nuclear export and related targets for the treatment of cancer and other diseases. The company is developing small molecule selective inhibitor of nuclear export (SINE) compounds that inhibit the nuclear export protein exportin 1. Its lead compound is XPOVIO (selinexor) tablets for the treatment of patients with heavily pretreated multiple myeloma and diffuse large B-cell lymphoma (DLBCL). The company develops BOSTON, which is in Phase 3 clinical trial for the treatment of patients with multiple myeloma; STORM, which is in Phase 2b single-arm clinical trial for evaluating oral selinexor in combination with standard, low-dose dexamethasone in heavily pretreated patients, relapsed or refractory myeloma; STOMP, which is in Phase 1b/2 multi-arm clinical trial for the treatment of low-dose dexamethasone plus standard therapies, including Velcade, Kyprolis, Revlimid, and Pomalyst or Darzalex; and SADAL, which is in Phase 2b clinical trial for the treatment of patients with relapsed or refractory DLBCL. It also develops SEAL, which is in Phase 3 clinical trial for the treartment of liposarcoma; SIENDO, which is in Phase 3 clinical trial for treatment of endometrial cancer; and KING, which is in Phase 2 for the treatment of glioblastoma multiforme brain tumor. In addition, the company has various investigational programs in clinical or preclinical development, such as Eltanexor (KPT-8602), KPT-9274, and Verdinexor (KPT-335). The company has collaboration agreement with Curadev Pharma Pvt Ltd to identify and co-develop novel small molecules against various biological targets for the treatment of cancer; and a cooperative research and development agreement with the National Cancer Institute for cancer therapy evaluation program. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.91 out of 5 stars

Medical Sector

114th out of 2,099 stocks

Pharmaceutical Preparations Industry

49th out of 830 stocks

Analyst Opinion: 3.4Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Karyopharm Therapeutics (NASDAQ:KPTI) Frequently Asked Questions

Is Karyopharm Therapeutics a buy right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Karyopharm Therapeutics in the last twelve months. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Karyopharm Therapeutics stock.
View analyst ratings for Karyopharm Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Karyopharm Therapeutics?

Wall Street analysts have given Karyopharm Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Karyopharm Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Karyopharm Therapeutics' next earnings date?

Karyopharm Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 3rd 2021.
View our earnings forecast for Karyopharm Therapeutics
.

How were Karyopharm Therapeutics' earnings last quarter?

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) issued its earnings results on Sunday, May, 2nd. The company reported ($0.77) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.71) by $0.06. The business earned $23.26 million during the quarter, compared to analyst estimates of $26.50 million. Karyopharm Therapeutics had a negative trailing twelve-month return on equity of 357.73% and a negative net margin of 177.34%.
View Karyopharm Therapeutics' earnings history
.

How has Karyopharm Therapeutics' stock price been impacted by Coronavirus?

Karyopharm Therapeutics' stock was trading at $21.24 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, KPTI stock has decreased by 51.4% and is now trading at $10.32.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for KPTI?

8 brokerages have issued 1-year price objectives for Karyopharm Therapeutics' stock. Their forecasts range from $15.00 to $41.00. On average, they expect Karyopharm Therapeutics' share price to reach $27.75 in the next year. This suggests a possible upside of 168.9% from the stock's current price.
View analysts' price targets for Karyopharm Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Karyopharm Therapeutics' key executives?

Karyopharm Therapeutics' management team includes the following people:
  • Mr. Richard A. Paulson M.B.A., Pres, CEO & Director (Age 54, Pay $52.38k)
  • Dr. Sharon Shacham, Co-Founder, Chief Scientific Officer & Chairman of Scientific Advisory Board (Age 51, Pay $720.1k)
  • Dr. Michael G. Kauffman, Co-Founder, Sr. Clinical Advisor & Director (Age 58, Pay $986.25k)
  • Mr. Michael P. Mason CPA, M.B.A., Sr. VP, CFO & Treasurer (Age 46, Pay $583.63k)
  • Dr. Mansoor Raza Mirza, Clinical Consultant, Member of Scientific Advisory Board & Director (Age 60, Pay $140.6k)
  • Mr. Ran Frenkel, Exec. VP & Chief Devel. Officer (Age 52)
  • Mr. Cameron Peters, VP of Fin., Assistant Treasurer & Principal Accounting Officer (Age 61)
  • Mr. Pierre S. Sayad M.S., Ph.D., VP of Global Medical & Scientific Affairs
  • Mr. Ian Karp M.B.A., Sr. VP of Investor & PR
  • Mr. Michael J. Mano J.D., Sr. VP, Gen. Counsel & Sec. (Age 46)

What is Michael Kauffman's approval rating as Karyopharm Therapeutics' CEO?

31 employees have rated Karyopharm Therapeutics CEO Michael Kauffman on Glassdoor.com. Michael Kauffman has an approval rating of 83% among Karyopharm Therapeutics' employees.

Who are some of Karyopharm Therapeutics' key competitors?

What other stocks do shareholders of Karyopharm Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Karyopharm Therapeutics investors own include NVIDIA (NVDA), Gilead Sciences (GILD), CRISPR Therapeutics (CRSP), Alibaba Group (BABA), Micron Technology (MU), Invitae (NVTA), Advanced Micro Devices (AMD), AbbVie (ABBV), Inovio Pharmaceuticals (INO) and Bristol-Myers Squibb (BMY).

What is Karyopharm Therapeutics' stock symbol?

Karyopharm Therapeutics trades on the NASDAQ under the ticker symbol "KPTI."

Who are Karyopharm Therapeutics' major shareholders?

Karyopharm Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (10.32%), Palo Alto Investors LP (7.14%), Morgan Stanley (2.26%), Goldman Sachs Group Inc. (1.61%), C WorldWide Group Holding A S (1.60%) and Geode Capital Management LLC (1.53%). Company insiders that own Karyopharm Therapeutics stock include Christopher Brett Primiano, Garen G Bohlin, Jatin Shah, John Demaree, Mansoor Raza Mirza, Michael Kauffman, Ran Frenkel, Sharon Shacham and Tanya Lewis.
View institutional ownership trends for Karyopharm Therapeutics
.

Which institutional investors are selling Karyopharm Therapeutics stock?

KPTI stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust, D. E. Shaw & Co. Inc., Price T Rowe Associates Inc. MD, Allianz Asset Management GmbH, Nuveen Asset Management LLC, and BNP Paribas Arbitrage SA. Company insiders that have sold Karyopharm Therapeutics company stock in the last year include Christopher Brett Primiano, Jatin Shah, Mansoor Raza Mirza, Michael Kauffman, Sharon Shacham, and Tanya Lewis.
View insider buying and selling activity for Karyopharm Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Karyopharm Therapeutics stock?

KPTI stock was bought by a variety of institutional investors in the last quarter, including Morgan Stanley, Compagnie Lombard Odier SCmA, C WorldWide Group Holding A S, Citigroup Inc., BlackRock Inc., Hennion & Walsh Asset Management Inc., Rafferty Asset Management LLC, and Schonfeld Strategic Advisors LLC. Company insiders that have bought Karyopharm Therapeutics stock in the last two years include Garen G Bohlin, Jatin Shah, and John Demaree.
View insider buying and selling activity for Karyopharm Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Karyopharm Therapeutics?

Shares of KPTI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Karyopharm Therapeutics' stock price today?

One share of KPTI stock can currently be purchased for approximately $10.32.

How much money does Karyopharm Therapeutics make?

Karyopharm Therapeutics has a market capitalization of $774.93 million and generates $108.08 million in revenue each year. The company earns $-196,270,000.00 in net income (profit) each year or ($2.72) on an earnings per share basis.

How many employees does Karyopharm Therapeutics have?

Karyopharm Therapeutics employs 432 workers across the globe.

What is Karyopharm Therapeutics' official website?

The official website for Karyopharm Therapeutics is www.karyopharm.com.

Where are Karyopharm Therapeutics' headquarters?

Karyopharm Therapeutics is headquartered at 85 WELLS AVENUE SECOND FLOOR, NEWTON MA, 02459.

How can I contact Karyopharm Therapeutics?

Karyopharm Therapeutics' mailing address is 85 WELLS AVENUE SECOND FLOOR, NEWTON MA, 02459. The company can be reached via phone at 617-658-0600 or via email at [email protected]


This page was last updated on 6/13/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.